Back to All Technologies

gary+aston-jones - Available Technologies | Rutgers University Innovation Ventures

Search Results - gary+aston-jones

2 Results

Sort By:

Chemogenetic Treatment for Neurodegenerative and Neuropsychiatric Disorders

yle> DREADD receptor-mediated activation of retinal cells prevents the development of light deprivation-induced depression-like behavior in vivo. A. DD-hM3Dq activation prevents the relative weight loss that was induced by constant dark lighting conditions. B. DREADD receptor-mediated activation of retinal cells leads to a reduction of depression-like...

Published: 10/3/2025 | Inventor(s): Gary Aston-Jones

Keywords(s):

Category(s): Technology Classifications > CNS Disorder, Technology Classifications > Gene Therapy, Technology Classifications > Therapeutics

Treatment for Neuropsychiatric Disorders by Intravitreal Injection of DREADD Followed by Eye Drops or Pills Containing DREADD agonist

Figure 1. DREADD receptor-mediated activation of retinal cells prevents the development of light deprivation-induced depression-like behavior in vivo. A. DD-hM3Dq activation prevents the relative weight loss that was induced by constant dark lighting conditions. B. DREADD receptor-mediated activation of retinal cells leads to a reduction of depression-like...

Published: 8/12/2025 | Inventor(s): Gary Aston-Jones, Hannah Bowrey

Keywords(s): Gene editing, Neurological disorder & neuropathic pain

Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics